Theriva Biologics, Inc. (TOVX)
USD 1.04
(-0.95%)
USD 1.04
(-0.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.43 Million USD | 0.7% |
| 2022 | -21.58 Million USD | -51.19% |
| 2021 | -14.27 Million USD | -40.49% |
| 2020 | -10.16 Million USD | 35.13% |
| 2019 | -15.66 Million USD | 10.86% |
| 2018 | -17.57 Million USD | 33.07% |
| 2017 | -26.25 Million USD | 33.12% |
| 2016 | -39.25 Million USD | 4.22% |
| 2015 | -40.98 Million USD | -99.88% |
| 2014 | -20.5 Million USD | -66.16% |
| 2013 | -12.33 Million USD | 28.67% |
| 2012 | -17.29 Million USD | -191.82% |
| 2011 | -5.92 Million USD | -274.25% |
| 2010 | -1.58 Million USD | 56.98% |
| 2009 | -3.68 Million USD | 49.7% |
| 2008 | -7.31 Million USD | 27.81% |
| 2007 | -10.13 Million USD | -146.25% |
| 2006 | -4.11 Million USD | -203.46% |
| 2005 | -1.35 Million USD | 0.0% |
| 2002 | -8.09 Million USD | 16.35% |
| 2001 | -9.67 Million USD | -53.66% |
| 2000 | -6.29 Million USD | -164.92% |
| 1999 | 9.7 Million USD | 18.3% |
| 1998 | 8.2 Million USD | 185.42% |
| 1997 | -9.6 Million USD | -31.51% |
| 1996 | -7.3 Million USD | 0.0% |
| 1995 | -7.3 Million USD | -14.06% |
| 1994 | -6.4 Million USD | -88.24% |
| 1993 | -3.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.42 Million USD | -57.42% |
| 2024 Q1 | -5.39 Million USD | 8.27% |
| 2023 Q4 | -5.87 Million USD | -39.36% |
| 2023 Q3 | -4.21 Million USD | 27.53% |
| 2023 Q1 | -5.17 Million USD | 29.36% |
| 2023 Q2 | -5.82 Million USD | -12.4% |
| 2023 FY | -22.09 Million USD | -2.36% |
| 2022 Q4 | -7.33 Million USD | -46.19% |
| 2022 Q3 | -5.01 Million USD | -0.58% |
| 2022 Q2 | -4.98 Million USD | -17.24% |
| 2022 Q1 | -4.25 Million USD | 19.24% |
| 2022 FY | -21.58 Million USD | -51.19% |
| 2021 Q4 | -5.26 Million USD | -60.76% |
| 2021 FY | -14.27 Million USD | -40.49% |
| 2021 Q1 | -2.53 Million USD | -19.0% |
| 2021 Q2 | -3.19 Million USD | -26.01% |
| 2021 Q3 | -3.27 Million USD | -2.44% |
| 2020 FY | -10.16 Million USD | 35.13% |
| 2020 Q1 | -3.02 Million USD | 5.67% |
| 2020 Q2 | -2.88 Million USD | 4.59% |
| 2020 Q3 | -2.11 Million USD | 26.93% |
| 2020 Q4 | -2.13 Million USD | -0.99% |
| 2019 Q2 | -3.63 Million USD | -1.85% |
| 2019 Q4 | -3.21 Million USD | 38.76% |
| 2019 Q3 | -5.24 Million USD | -44.09% |
| 2019 FY | -15.66 Million USD | 10.86% |
| 2019 Q1 | -3.57 Million USD | -9.64% |
| 2018 Q2 | -5 Million USD | -0.26% |
| 2018 Q1 | -4.99 Million USD | 13.71% |
| 2018 Q3 | -4.32 Million USD | 13.65% |
| 2018 FY | -17.57 Million USD | 33.07% |
| 2018 Q4 | -3.25 Million USD | 24.58% |
| 2017 Q3 | -5.84 Million USD | 9.78% |
| 2017 Q1 | -8.14 Million USD | 20.14% |
| 2017 Q4 | -5.78 Million USD | 1.01% |
| 2017 FY | -26.25 Million USD | 33.12% |
| 2017 Q2 | -6.47 Million USD | 20.54% |
| 2016 Q4 | -10.2 Million USD | -11.45% |
| 2016 Q1 | -10.58 Million USD | 7.13% |
| 2016 Q2 | -9.31 Million USD | 12.0% |
| 2016 Q3 | -9.15 Million USD | 1.66% |
| 2016 FY | -39.25 Million USD | 4.22% |
| 2015 Q3 | -11.65 Million USD | -19.73% |
| 2015 Q2 | -9.73 Million USD | -18.56% |
| 2015 Q1 | -8.2 Million USD | -15.58% |
| 2015 FY | -40.98 Million USD | -99.88% |
| 2015 Q4 | -11.39 Million USD | 2.21% |
| 2014 Q2 | -4.65 Million USD | -21.15% |
| 2014 Q1 | -3.83 Million USD | 10.16% |
| 2014 Q4 | -7.1 Million USD | -44.59% |
| 2014 FY | -20.5 Million USD | -66.16% |
| 2014 Q3 | -4.91 Million USD | -5.59% |
| 2013 FY | -12.33 Million USD | 28.67% |
| 2013 Q3 | -3.36 Million USD | -36.73% |
| 2013 Q4 | -4.27 Million USD | -26.98% |
| 2013 Q1 | -2.24 Million USD | 81.15% |
| 2013 Q2 | -2.46 Million USD | -9.87% |
| 2012 Q3 | -1.83 Million USD | -6.56% |
| 2012 Q4 | -11.88 Million USD | -547.39% |
| 2012 FY | -17.29 Million USD | -191.82% |
| 2012 Q2 | -1.72 Million USD | 7.07% |
| 2012 Q1 | -1.85 Million USD | 29.87% |
| 2011 Q1 | -1.42 Million USD | -93.89% |
| 2011 Q2 | -919.5 Thousand USD | 35.54% |
| 2011 Q3 | -938.22 Thousand USD | -2.04% |
| 2011 Q4 | -2.64 Million USD | -181.77% |
| 2011 FY | -5.92 Million USD | -274.25% |
| 2010 Q1 | -1.09 Million USD | 0.78% |
| 2010 FY | -1.58 Million USD | 56.98% |
| 2010 Q2 | 973.28 Thousand USD | 188.91% |
| 2010 Q4 | -735.74 Thousand USD | -0.36% |
| 2010 Q3 | -733.12 Thousand USD | -175.33% |
| 2009 Q3 | -626.22 Thousand USD | 28.81% |
| 2009 FY | -3.68 Million USD | 49.7% |
| 2009 Q2 | -879.6 Thousand USD | 19.26% |
| 2009 Q1 | -1.08 Million USD | -18.4% |
| 2009 Q4 | -1.1 Million USD | -76.17% |
| 2008 FY | -7.31 Million USD | 27.81% |
| 2008 Q2 | -1.8 Million USD | 42.38% |
| 2008 Q4 | -920.09 Thousand USD | 37.41% |
| 2008 Q3 | -1.46 Million USD | 18.42% |
| 2008 Q1 | -3.12 Million USD | 2.77% |
| 2007 Q3 | -2.17 Million USD | -18.88% |
| 2007 Q1 | -2.92 Million USD | 28.92% |
| 2007 Q2 | -1.82 Million USD | 37.42% |
| 2007 FY | -10.13 Million USD | -146.25% |
| 2007 Q4 | -3.21 Million USD | -48.02% |
| 2006 Q1 | -515.53 Thousand USD | 0.0% |
| 2006 Q2 | -4363.00 USD | 99.15% |
| 2006 Q3 | -3017.00 USD | 30.85% |
| 2006 FY | -4.11 Million USD | -203.46% |
| 2006 Q4 | -4.1 Million USD | -136118.0% |
| 2005 FY | -1.35 Million USD | 0.0% |
| 2003 Q1 | -574.08 Thousand USD | 28.99% |
| 2002 Q3 | -1.13 Million USD | 62.72% |
| 2002 FY | -8.09 Million USD | 16.35% |
| 2002 Q1 | -3.09 Million USD | -3.92% |
| 2002 Q2 | -3.05 Million USD | 1.22% |
| 2002 Q4 | -808.45 Thousand USD | 29.01% |
| 2001 Q3 | -2.71 Million USD | -15.13% |
| 2001 Q2 | -2.36 Million USD | -45.42% |
| 2001 Q1 | -1.62 Million USD | 13.92% |
| 2001 FY | -9.67 Million USD | -53.66% |
| 2001 Q4 | -2.97 Million USD | -9.5% |
| 2000 Q1 | -1.47 Million USD | -7.54% |
| 2000 Q4 | -1.88 Million USD | -31.47% |
| 2000 Q3 | -1.43 Million USD | 4.52% |
| 2000 Q2 | -1.5 Million USD | -1.81% |
| 2000 FY | -6.29 Million USD | -164.92% |
| 1999 Q2 | -1.3 Million USD | -18.18% |
| 1999 FY | 9.7 Million USD | 18.3% |
| 1999 Q1 | -1.1 Million USD | 0.0% |
| 1999 Q4 | -1.37 Million USD | 8.52% |
| 1999 Q3 | -1.5 Million USD | -15.38% |
| 1998 Q3 | -400 Thousand USD | -103.39% |
| 1998 Q4 | -1.1 Million USD | -175.0% |
| 1998 FY | 8.2 Million USD | 185.42% |
| 1998 Q2 | 11.8 Million USD | 661.9% |
| 1998 Q1 | -2.1 Million USD | -31.25% |
| 1997 Q4 | -1.6 Million USD | 11.11% |
| 1997 Q2 | -3.3 Million USD | -26.92% |
| 1997 Q1 | -2.6 Million USD | -13.04% |
| 1997 FY | -9.6 Million USD | -31.51% |
| 1997 Q3 | -1.8 Million USD | 45.45% |
| 1996 Q1 | -1.6 Million USD | 15.79% |
| 1996 Q2 | -1.6 Million USD | 0.0% |
| 1996 Q4 | -2.3 Million USD | -35.29% |
| 1996 Q3 | -1.7 Million USD | -6.25% |
| 1996 FY | -7.3 Million USD | 0.0% |
| 1995 Q4 | -1.9 Million USD | 5.0% |
| 1995 Q1 | 100 Thousand USD | 101.56% |
| 1995 FY | -7.3 Million USD | -14.06% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q3 | -2 Million USD | -2100.0% |
| 1994 Q2 | 100 Thousand USD | 133.33% |
| 1994 Q1 | -300 Thousand USD | 75.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | -6.4 Million USD | -88.24% |
| 1994 Q4 | -6.4 Million USD | -6500.0% |
| 1993 Q3 | -1.4 Million USD | -250.0% |
| 1993 FY | -3.4 Million USD | 0.0% |
| 1993 Q1 | -300 Thousand USD | 0.0% |
| 1993 Q4 | -1.2 Million USD | 14.29% |
| 1993 Q2 | -400 Thousand USD | -33.33% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 32.852% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -125.163% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 47.589% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 58.723% |
| Azitra, Inc. | -7.61 Million USD | -181.38% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -161.513% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -212.301% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 26.08% |
| CEL-SCI Corporation | -31.47 Million USD | 31.913% |
| iBio, Inc. | -16.63 Million USD | -28.839% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 13.351% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -6.187% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 9.825% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -52.524% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -328.363% |
| NanoViricides, Inc. | -8.51 Million USD | -151.652% |
| Oragenics, Inc. | -20.9 Million USD | -2.517% |
| BiomX Inc. | -27.68 Million USD | 22.59% |
| BiomX Inc. | -27.68 Million USD | 22.59% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 304.885% |
| Palatin Technologies, Inc. | -22.49 Million USD | 4.735% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 49.013% |